

This is the accepted manuscript version of the contribution published as:

Gyllenhammar, I., Benskin, J.P., Sandblom, O., **Berger, U.**, Ahrens, L., Lignell, S., Wiberg, K., Glynn, A. (2019):
Perfluoroalkyl acids (PFAAs) in children's serum and contribution from PFAA-contaminated drinking water
Environ. Sci. Technol. **53** (19), 11447 - 11457

The publisher's version is available at:

<https://doi.org/10.1021/acs.est.9b01746>

Perfluoroalkyl acids (PFAAs) in children's serum and contribution from PFAA contaminated drinking water

Irina Gyllenhammar, Jonathan P. Benskin, Oskar Sandblom, Urs Berger, Lutz Ahrens, Sanna Lignell, Karin Wiberg, and Anders Glynn

Environ. Sci. Technol., **Just Accepted Manuscript** • DOI: 10.1021/acs.est.9b01746 • Publication Date (Web): 02 Sep 2019

Downloaded from pubs.acs.org on September 2, 2019

Just Accepted

"Just Accepted" manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides "Just Accepted" as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. "Just Accepted" manuscripts appear in full in PDF format accompanied by an HTML abstract. "Just Accepted" manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). "Just Accepted" is an optional service offered to authors. Therefore, the "Just Accepted" Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the "Just Accepted" Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these "Just Accepted" manuscripts.

1 **Perfluoroalkyl acids (PFAAs) in children's serum and contribution from PFAA**
2 **contaminated drinking water**

3 Irina Gyllenhammar,^{†*} Jonathan P. Benskin,[‡] Oskar Sandblom,[‡] Urs Berger,[§] Lutz Ahrens,[#]
4 Sanna Lignell,[†] Karin Wiberg,[#] Anders Glynn[□]

5 [†]Department of Risk and Benefit Assessment, National Food Agency, P.O. Box 622, SE-751
6 26 Uppsala, Sweden

7 [‡]Department of Environmental Science and Analytical Chemistry (ACES), Stockholm
8 University, SE-106 91 Stockholm, Sweden

9 [§]Helmholtz Centre for Environmental Research (UFZ), Department Analytical Chemistry,
10 Permoserstr. 15, DE-04318 Leipzig, Germany

11 [#]Department of Aquatic Sciences and Assessment, Swedish University of Agricultural
12 Sciences (SLU), Box 7050, SE-750 07, Uppsala, Sweden

13 [□]Department of Biomedical Sciences and Veterinary Public Health, Swedish University of
14 Agricultural Sciences (SLU), Box 7028, SE-750 07, Uppsala, Sweden

15

16

17

18 ***Corresponding author:**

19 Irina Gyllenhammar

20 Department of Risk and Benefit Assessment, National Food Agency, P.O. Box 622, SE-751

21 26 Uppsala, Sweden Telephone: int + 46 18 174326


22 E-mail: irina.gyllenhammar@slv.se

23

24 **Abstract**

25 We investigated associations between serum perfluoroalkyl acid (PFAA) concentrations in
26 children aged 4, 8, and 12 years (sampled in 2008-2015; $n=57$, 55, and 119, respectively) and
27 exposure via placental transfer, breast-feeding, and ingestion of PFAA-contaminated drinking
28 water. Sampling took place in Uppsala County, Sweden, where the drinking water has been
29 historically contaminated with perfluorobutanesulfonate (PFBS), perfluorohexanesulfonate
30 (PFHxS), perfluorooctanesulfonate (PFOS), perfluoroheptanoate (PFHpA), and
31 perfluorooctanoate (PFOA). PFOS showed the highest median concentrations in serum (3.8-
32 5.3 ng g⁻¹ serum) followed by PFHxS (1.6-5.0 ng g⁻¹ serum), PFOA (2.0-2.5 ng g⁻¹ serum),
33 and perfluorononanoate (PFNA) (0.59-0.69 ng g⁻¹ serum) in children. Including all children,
34 serum PFOA, PFHxS, and PFOS concentrations in children increased 10%, 10%, and 1.3%
35 (adjusted mean), respectively, per unit (ng g⁻¹ serum) of increase in maternal serum level (at
36 delivery), the associations being strongest for 4-year-old children. PFHxS and PFOS
37 significantly increased 3.9% and 3.8%, respectively, per month of nursing, with the highest
38 increase for 4-year-olds. PFOA, PFBS, PFHxS, and PFOS increased 1.2%, 207%, 7.4%, and
39 0.93%, respectively, per month of cumulative drinking water exposure. Early life exposure to
40 PFOA, PFHxS, and PFOS is an important determinant of serum concentrations in children,
41 with the strongest influence on younger ages. Drinking water with low to moderate PFBS,
42 PFHxS, PFOS, and PFOA contamination is an important source of exposure for children with
43 background exposure from other sources.

44 **TOC Graphic**



45

46 **Introduction**

47 Per- and polyfluoroalkyl substances (PFASs) are synthetic highly fluorinated substances that
48 have been produced in large volumes and which have broad commercial applications. PFASs
49 are ubiquitous in humans and the environment. Human exposure media include food, drinking
50 water, dust, air and products containing PFASs.^{1 2 3} Perfluoroalkyl acids (PFAAs) are a class
51 of PFASs which are intentionally manufactured, but which may also occur from degradation
52 of other PFASs (i.e. PFAA-precursors).^{4 5} PFAAs display extreme environmental persistence
53 and chain length-dependent bioaccumulation in humans.^{6, 7}

54 For the general population, exposure to PFAAs via placental transfer⁸⁻¹¹ and ingestion of
55 mother's milk¹²⁻¹⁴ are major determinants of blood PFAAs concentrations in infants.¹⁵⁻²⁰ In
56 fact, exposure to certain PFAAs via breast milk as an infant represents a significant fraction of
57 a child's overall exposure up to 3-5 years of age, most probably due to the long half-lives of
58 these PFAAs in the body.^{21, 22} Other exposure media like diet, drinking water, dust and air
59 contribute to a greater extent as the child gets older.²²⁻²⁶ Early life exposure to some PFAAs
60 during pregnancy has been associated with lower birth weight²⁷⁻²⁹ and increased childhood
61 adiposity.³⁰⁻³³ Positive associations between maternal PFAA levels during pregnancy and
62 children's weight or body mass index (BMI) have also been reported^{29, 31, 34} along with
63 relations to immune toxicity in children.^{35, 36} Improved knowledge of the determinants of
64 blood PFAA concentrations in infants/children, in particular in scenarios involving point
65 source contamination (e.g. contaminated drinking water) is needed for understanding the
66 exposure sources responsible for observed relationships between blood PFAA concentrations
67 and health outcomes.

68 Drinking water in the City of Uppsala, Sweden, was contaminated with PFAAs for at least 20
69 years³⁷ before the contamination was discovered in 2012 and affected production wells were

70 closed or severely restricted. Perfluorohexane sulfonate (PFHxS) was the most prevalent
71 PFAA in the contaminated production wells at the time of well closure (mean 80 ng L⁻¹)
72 followed by perfluorooctane sulfonate (PFOS; 50 ng L⁻¹) and perfluorobutane sulfonate
73 (PFBS; 10 ng L⁻¹)³⁷. Uppsala is thus a good setting for studies investigating different sources
74 of PFAA exposure (e.g. trans-placental transfer, mother's milk, drinking water) as
75 determinants of blood PFAA concentrations during childhood.

76 In a previous study of 2-4-month-old infants from Uppsala participating in the POPUP cohort
77 (Persistent Organic Pollutants in Uppsala Primiparas) it was shown that prenatal and postnatal
78 PFAA exposure significantly contributed to the serum concentrations in infants and that
79 maternal PFHxS and PFBS exposure from drinking water was an important indirect infant
80 exposure source.³⁸

81 The aim of the present study was to investigate determinants of PFAA serum concentrations
82 in older children at ages 4, 8, and 12 years, from the POPUP cohort, focussing on maternal
83 PFAA concentrations at the time of delivery, nursing history of the child, and history of
84 drinking water exposure of the child. Specific research objectives addressed here include: a)
85 determining the contribution of PFAA exposure *in utero* and during nursing at different ages
86 of children and b) to assess the extent to which PFAA exposure via medium grade
87 contaminated drinking water (10-100 ng/l of single PFAAs) is a determinant of PFAA serum
88 concentrations during childhood in a population with background exposure from other
89 sources.

90

91 **Materials and methods**

92 **Sampling**

93 All mother/child pairs included in the present paper are participants in the POPUP study, an
94 on-going investigation of POPs in first-time mothers and their children in Uppsala County,
95 Sweden. Mothers were randomly recruited during pregnancy (1996-1999) or shortly after
96 delivery (2000-2011).^{39, 40} The mothers answered a self-administered questionnaire about life-
97 style factors and health of the mother and child. Information about nursing was given by the
98 mother, answering for each month after birth up to 13 months, if the child had been only-, part
99 time-, or not breastfeeding. Blood samples from the mothers were collected 3 weeks after
100 delivery. Following up on this, serum samples were collected from the children when they
101 were 4-, 8-, and 12 years of age between 2008 and 2015 ($n=57$, $n=55$, and $n=119$,
102 respectively; Fig. 1). None of the children were sampled at all ages, in total 33 children were
103 sampled twice ($n=13$ at age 4 and 8 and $n=20$ at age 8 and 12). Detailed characteristics of the
104 children are provided in Table 1. Plastic Vacutainer[®] or Vacuette[®] serum tubes were used for
105 blood sampling and serum was stored at -20°C until analysis. The study was approved by the
106 local ethics committee in Uppsala, Sweden (dnr 2004/177 and 2007/147/1), and the
107 participating women and children gave informed consent.

108

109 **Chemical analyses**

110 A total of 13 PFAAs were targeted in the present work, including C_4 , C_6 and C_8
111 perfluoroalkane sulfonic acids (PFSA; i.e. PFBS, PFHxS, PFOS) and C_6 - C_{15} perfluoroalkyl
112 carboxylic acids (PFCA; i.e. PFHxA, PFHpA, PFOA, PFNA, PFDA, PFUnDA, PFDoDA,
113 PFTrDA, PFTeDA, PFPeDA; for details see Supporting Information, Table A1). The serum
114 samples were analysed as described previously.³⁷ In short, 0.5 g serum was spiked with
115 internal standards and extracted with acetonitrile in an ultrasonic bath. The concentrated

116 extract underwent dispersive clean-up with graphitized carbon. Aqueous ammonium acetate
117 and volumetric standards were added before analysis on an Acquity ultra performance liquid
118 chromatography system (UPLC) coupled to a Xevo TQ-S tandem mass spectrometer
119 (MS/MS; both Waters Corp., Milford, MA, U.S.) operated in negative electrospray ionization,
120 multiple reaction monitoring mode. Instrumental parameters are provided in Supporting
121 Information, Table A2.

122 Quantification was performed by isotope dilution using a 5-point calibration curve (linear, 1/x
123 weighting), which was run before and after samples. For most targets, analogous isotopically
124 labelled internal standards were available. For PFBS, PFTrDA, PFTeDA, and PFPeDA, a
125 structurally similar internal standard was used (Supporting Information, Table A2). For
126 PFHxS and PFOS, Σ branched (br) and linear (lin) isomers were quantified separately using
127 the calibration curve for the lin isomer and the concentrations for the m/z 499/80 and 499/99
128 product ions were averaged, as described in Riddell et al.⁴¹

129 A procedural blank and a quality control (QC) sample (pooled human serum analyzed
130 repeatedly in-house) were included with every batch of samples to assess background
131 contamination and reproducibility, respectively (see Supporting Information Table A3 for QC
132 performance metrics). In addition, three replicates of standardized and certified reference
133 material from NIST (SRM 1957) were analyzed, and quantified concentrations were
134 compared to reference values to assess method accuracy (results provided in Supporting
135 Information Tables A4 and A5). Measured concentrations in SRM 1957 were consistent with
136 reference values for all targets, while CVs in control serum ($n=8$) ranged from 11-30%, with
137 the exception of PFBS (41%), which was close to detection limits and only intermittently
138 detected in control serum. For targets observable in method blanks, the detection limit was
139 based on the mean blank + $3\times$ the standard deviation of the blanks. For targets absent in
140 blanks, detection limits were based on a signal to noise ratio of 3. The method quantification

141 limits (MQL) were 0.16 ng g⁻¹ serum for PFHxA, 0.08 ng g⁻¹ serum for PFHpA, 0.8 ng g⁻¹
142 serum for PFOA, 0.08 ng g⁻¹ serum for PFNA, 0.10 ng g⁻¹ serum for PFDA and PFUnDA,
143 0.08 ng g⁻¹ serum for PFDoDA, 0.02 ng g⁻¹ serum for PFTrDA, 0.06 ng g⁻¹ serum for
144 PFTeDA, 0.01 ng g⁻¹ serum for PFPeDA, 0.01 ng g⁻¹ serum for PFBS, PFHxS, and PFOS.

145

146 **Exposure via drinking water**

147 Data on the occurrence of PFAAs in drinking water were only available for a few samples
148 ($n=9$) collected at the tap in different parts of Uppsala County in 2012, when PFAA
149 contamination was first discovered.⁴² A study of PFAA concentrations in maternal serum
150 from 1996 to 2011 revealed that the drinking water was already contaminated during the
151 initial study period (1996-1999).³⁷ Modeling the distribution of contaminated well water from
152 1996 to 2012 made it possible to estimate the extent of exposure to PFAA-contaminated water
153 depending on location of residence within Uppsala County.³⁷

154 The cumulative number of months with PFAA exposure from drinking water (DW_{cumexp}) were
155 calculated for the five PFAAs that were detected in the drinking water: PFHpA, PFOA,
156 PFBS, PFHxS, and PFOS. Details of the distribution patterns of PFAA-contaminated drinking
157 water in Uppsala City from 1996 to 2012 were collected, and an overview of the distribution
158 was obtained by modeling.³⁷ This information revealed that residential addresses of the
159 children over the duration of the study (data obtained from the Swedish Population Register)
160 could be divided into four different PFAA drinking water districts (up to July 2012; thereafter
161 contamination was mitigated), with District 1 not receiving a contribution from PFAA-
162 contaminated wells, and Districts 2, 3, and 4 receiving contributions of <10%, 10-89% and
163 $\geq 90\%$, respectively, from the contaminated wells. In the calculations of the DW_{cumexp} each
164 child was assigned to a district based on home address for each month of life until blood

165 sampling. Children assigned to District 1 were estimated to have been exposed to 0% of the
 166 contaminated water on a monthly basis ($DW_{exp}=0$), while children in Districts 2, 3, and 4
 167 were estimated to have been exposed to 5%, 50%, and 95%, respectively, of contaminated
 168 water ($DW_{exp}=0.05, 0.50, \text{ and } 0.95$). After July 2012, it was assumed that no district received
 169 contaminated water (i.e. $DW_{exp} = 0$).

170 In the next step, each DW_{exp} was half-life-adjusted based on the number of months between
 171 the month in question and blood sampling. The half-lives ($T^{1/2}$) used were 70 days (2.3
 172 months) for PFHpA,⁴³ 26 days (0.87 months) for PFBS,⁴⁴ 2.7 years (32 months) for PFOA,
 173 5.3 years (64 months) for PFHxS, and 3.4 years (41 months) for PFOS.⁴⁵

174 Each participant's cumulative number of months with exposure to a given PFAA from
 175 drinking water (DW_{cumexp}) could thus be estimated by the formula: (see Supporting
 176 Information Table A6 for example calculations).

$$177 \quad DW_{cumexp} = \sum_{i=1}^n DW_{exp_i} * \frac{1^{(n-i)/T}}{2}$$

178 DW_{exp_i} = proportion of contaminated water in the drinking water during month i (0, 0.05, 0.5, or 0.95)

179 $T^{1/2}$ = half-life of the PFAA

180 n = number of months from birth to blood sampling, i.e. $(n-i)$ = number of months from month i to
 181 blood sampling)

182

183 **Statistical analyses**

184 MINITAB 15® Statistical Software for Windows was used for all statistical analyses. When
 185 PFAA concentrations were below the MQL, $MQL/\sqrt{2}$ was used in the statistical analyses. The

186 proportions of *br* and *lin* isomers for PFHxS and PFOS were expressed as a percentage of the
187 total concentration. Correlations among serum PFAAs were investigated using average
188 linkage cluster analysis, which is a hierarchical analysis clustering method based on the
189 average distance between all pairs of objects. Kruskal-Wallis test was used to evaluate
190 possible differences in serum PFAA concentrations among children aged 4, 8, and 12 years.
191 General linear model (GLM) analysis was used to investigate differences in serum PFAA
192 concentrations between age groups, adjusted for sampling year and drinking water exposure.
193 Multiple linear regressions (MLR) were used to analyze associations between PFAA
194 concentrations in child serum and maternal PFAA level at delivery, duration of breastfeeding
195 during infancy, and childhood drinking water exposure. When analyzing *br* PFHxS or
196 PFOS in children, the maternal serum *br* PFHxS or PFOS was included instead of maternal
197 concentrations of PFHxS or PFOS. These MLR analyses were not performed for PFAAs
198 where >25% of the reported concentrations were below MQL, except for PFHpA and PFBS
199 when analyzing the influence of drinking water exposure on serum concentrations. PFHpA
200 and PFBS have relatively short serum half-lives (70 and 26 days, respectively^{43, 44});
201 consequently, maternal PFAA levels at delivery and duration of breastfeeding are not
202 expected to make a significant contribution to serum PFAA levels in children and were
203 therefore not included as exposure sources. The associations between child PFAA
204 concentrations and other determinants (i.e. age at sampling, sampling year, body weight, and
205 sex) were first analyzed in univariate linear analyses and those associated with PFAA
206 concentrations at $p \leq 0.1$ significance levels were included in the MLR model.

207 In addition, stepwise regression was used to estimate how much of the variation in PFAA
208 concentrations was explained by the variation of the determining factors. Logarithmically-
209 transformed PFAA concentrations were used in the statistical analyses, since the distribution
210 of data closely followed a log-normal distribution. As a consequence, partial regression

211 coefficients (β) of the independent variables may be interpreted as % change in serum
212 concentrations of PFAA per unit of change in the independent variable, calculated as
213 $\%change = (1 - \exp(\beta)) * 100$. In the analyses of all children (aged 4, 8, and 12) together, only
214 results from one sampling age were used for children that were sampled more than once
215 ($n=33$). For children sampled both at 8 and 12 years of age, the results from age 8 were used,
216 due to a smaller sample size than among 12-year-old children. Children sampled both at 4 and
217 8 years of age were allocated equally into the two age groups, as the sample sizes were
218 similar. A sensitivity test was performed when observations with standardized residuals ≥ 3
219 were excluded from analysis due to their large influence on the regression results. The
220 statistical significance was set to $p \leq 0.05$.

221

222 **Results and discussion**

223 **PFAA serum concentrations**

224 PFAA serum concentrations in children at different ages are presented in Table 2 (PFCAs)
225 and Table 3 (PFSAs). For the investigated sampling years (i.e. 2008-2015), total PFOS, total
226 PFHxS, and PFOA displayed the highest median concentrations in children's serum, in all age
227 groups. Significant differences were observed between PFAA concentrations in 4-, 8-, and
228 12-year-olds ($p < 0.05$; Kruskal-Wallis test) for all detected targets, except PUnDA, PTrDA,
229 and PFBS. For PFHpA, PFOA, and PFHxS the highest concentrations were observed in 4-
230 year-olds, while PFOS concentrations increased with increasing age. No general age-
231 dependent pattern was observed for PFNA and PFDA. However, due to differences in timing
232 of sampling between age groups (Fig. 1) and possible differences in drinking water exposure,
233 it is more relevant to compare age-dependent differences in concentrations after adjustment of
234 concentrations for sampling year and half-life-adjusted months of contaminated drinking

235 water. In this case (using GLM), PFHpA, PFOA, and PFHxS serum concentrations were
236 significantly higher among 4-year-old children compared to 8- and 12-year-olds (Fig. 2), and
237 PFHpA, PFNA and PFDA were significantly higher in 8- compared to 12-year-olds.

238 For comparison, blood PFAA concentrations in children from other studies during the same
239 time period are provided in the Supporting Information, Table A7. Studies reporting age-
240 dependent differences in PFAA concentrations among children have observed diverging
241 results.^{46, 47 36, 48 49 50 51-53} The comparisons are, however, hampered by differences among
242 studies with respect to study design, location, child age, nursing history, and sampling year.

243 Taking these uncertainties into account, there are few marked differences in PFAA
244 concentrations between children from Uppsala examined in the present study, and those with
245 background exposure from Denmark, the Faroe Islands, Germany, and the U.S.^{46, 47 36, 48 49 50}
246 ⁵¹ The few exceptions include PFNA, where higher serum levels were reported in two studies
247 from the U.S.,^{46, 47} and PFHxS, where concentrations in children's serum in the present study
248 are elevated, most likely due to drinking water exposure.³⁷ Moreover, 3-6-fold higher
249 concentrations of PFOS, PFDA, PFUnDA, and PFTrDA, and 30-fold higher concentrations of
250 PFBS were reported in serum from children in South Korea and Taiwan compared to the
251 present study.^{52, 53}

252 Historical production of PFOS, its salts and derivatives by the major global manufacturer (the
253 3M Company) resulted in a technical mixture of about 70% lin and 30% Σ br isomers.⁵ The
254 major technical PFOS mixture (3M) contained impurities of PFHxS consisting of about 82%
255 lin and 18% br PFHxS isomers.⁵⁴ Previous studies in adults have reported a slightly higher
256 percentage of br PFOS isomers in human serum than in the historical technical mixture.^{37, 55}
257 This is supported by our finding of 37% br PFOS isomers (median) in POPUP children (Table
258 3). The %br PFHxS and PFOS are in agreement with the values observed in 3-month-old
259 POPUP infants and their mothers sampled in 1996-1999.³⁸ The differences in %br PFHxS and

260 PFOS in children in relation to technical mixtures may for instance be due to differences in
261 historical PFHxS and PFOS exposure patterns and sources or how the content of br isomers
262 has been determined analytically. The difference may also be explained by different
263 toxicokinetics of lin and br isomers in humans^{9,56} or that the children in the present study
264 have been exposed to PFAS-contaminated drinking water (see discussion below). Studies of
265 PFAA isomers in children are scarce, and to our knowledge this is the first study of serum
266 concentrations of br and lin PFHxS in children. In Danish children aged 6-11 years sampled
267 in 2011, the median br PFOS content in serum was 32%⁴⁸ and 29% in children aged 6-10
268 years sampled 2007-2010 in the U.S.⁴⁶ We did not observe any age differences in %br PFOS
269 and PFHxS isomers in the Uppsala children (Table 3), suggesting that differences in
270 elimination rates between br and lin isomers⁵⁷ are not significant determinants of the
271 proportions of br and lin isomers in serum during childhood.

272 Cluster analysis of PFAA based on correlations between serum concentrations in 4-, 8-, and
273 12-year-old children are shown in Figure 3. PFBS and PFHxS clustered together in the
274 children in the present study, which may be due to drinking water being a common source of
275 exposure in the Uppsala children, as shown in their mothers.³⁷ Long-chain PFCAs and PFOS
276 clustered separately from PFBS and PFHxS as well as from PFOA and PFHpA (Fig. 3). Apart
277 from drinking water exposure as a possible explanation to the separate clustering of PFBS and
278 PFHxS, differences in dietary sources could explain separate clustering of long-chain
279 PFCAs/PFOS and PFOA. A study of PFASs in food on the Swedish market showed that in
280 2010 fish consumption contributed with more than 80% of total per capita exposure of long-
281 chain PFCAs and PFOS from food, whereas PFOA intake from fish consumption was
282 estimated to be $\leq 10\%$ of total per capita exposure.³ Sub-clustering of PFUnDA and PFTrDA
283 separately from PFNA, PFDA, and PFOS within the same hierarchy (Fig. 3) points to fish

284 consumption as a common source of exposure to these PFASs, but more so for PFUnDA and
285 PFTrDA compared to PFNA, PFDA, and PFOS.³

286

287 **Determinants for PFAA in children sampled 2008-2015**

288 All 4-, 8-, and 12-year-old children were first analyzed together in order to increase statistical
289 power (n=198), and the results are given in table 4. In the next step, the different age groups
290 were analyzed separately to determine age-related difference regarding associations between
291 maternal concentrations at delivery and breastfeeding duration and child concentrations
292 (Table 5). In Supporting Information, the results from all analyzed PFAA at the different ages
293 are presented in table A10.

294 In the MLR analyses, including all children, age-dependent differences in adjusted mean
295 PFAA concentrations were less obvious (Supporting Information, Table A8) than in the
296 GLM-analyses adjusting only for sampling year and drinking water exposure (Fig. 2).
297 Consequently, the age differences observed in the GLM-analyses after adjustment for only
298 sampling year and drinking water exposure were to some extent due to the influence of the
299 other determinants of serum PFAA concentrations investigated in the present work, such as
300 maternal serum concentration, breastfeeding, weight, and sex (Table 4).

301 The influence of fetal and postnatal lactation exposure on child serum PFAA levels was
302 investigated by including the variables “maternal serum concentrations at delivery” and
303 “breastfeeding duration” in the MLR model, except for PFHpA and PFBS, which have
304 relatively short half-lives in serum. When including all children in the MLR analyses,
305 increased maternal serum concentrations (at delivery) were associated with increased child
306 serum concentration for PFHxS (coefficient of determination (R^2)=0.11), PFOA (R^2 =0.04),
307 and PFOS (R^2 =0.03).

308 Maternal PFAA concentrations at birth most probably reflect both *in utero* and lactational
309 exposure of the children, since maternal serum/plasma concentrations of PFHxS, PFOS,
310 PFOA, PFNA, PFDA, and PFUnDA during pregnancy and close to delivery are strongly
311 correlated with PFAA concentrations both in cord blood and mother's milk.^{12, 18 58 8 19 59} For
312 PFOA, PFHxS and PFOS, the impact of early exposure was greater in 4-year-old children
313 compared to the older age groups (Table 5). For example, PFOA serum concentrations in the
314 4-year-olds increased 29% per unit (ng g⁻¹ serum) of increase in maternal serum PFOA level
315 ($R^2=0.24$), whereas in 12-year-olds the increase was 8.4% ($R^2=0.04$).

316 The strong association between levels of PFOA, PFHxS, and PFOS in serum of mothers at the
317 time of delivery and 4-year-olds but not in the older age groups may be due to a combination
318 of growth dilution of PFAAs accumulated *in utero* and during nursing, a longer period of
319 excretion of PFAAs that were accumulated early in life among the older children, and an
320 increased contribution of PFAAs accumulated for instance from food among older children.
321 For the long-chain PFCAs, PFNA and PFDA, we observed no associations between early life
322 exposure and serum concentrations in the children, suggesting that early life exposure to these
323 PFAAs have little influence on concentrations later in childhood. Similarly, in 3-month-old
324 POPUP infants the influence of maternal PFAA concentrations at delivery decreased with
325 increasing perfluoroalkyl chain length.³⁸ Factors other than early life exposure are apparently
326 more important in determining concentrations of PFDA and PFNA than for PFOA, PFHxS,
327 and PFOS.

328 Percent of br PFOS in children increased with increasing %br in maternal serum at delivery,
329 whereas no such association was found for PFHxS (Tables 4 and 5). When stratifying for
330 child age, the associations for %br PFOS were positive in all three age groups but only
331 significant for 8- and 12-year-olds. The positive association between %br PFOS in mothers at
332 delivery and %br PFOS in the children suggest significant maternal influence on PFOS

333 isomer patterns in children for many years after birth. This could, apart from the remaining
334 influence from *in utero* and breastfeeding exposure, mirror similar food habits and exposure
335 sources between mothers and their children.

336 PFOA (only in 4-year-olds), PFHxS, and PFOS were associated with breastfeeding duration,
337 showing an increase with increased breastfeeding duration with partial $R^2=0.01$ and 0.04 , for
338 PFHxS and PFOS respectively and 0.05 for PFOA in 4-year-olds (Table 4 and 5). As shown
339 by the R^2 s, only a small percentage of variation of child PFAA concentrations were explained
340 by the *in utero* and breastfeeding exposure, most likely due to greater contribution of PFAA
341 exposure during the years after cessation of breastfeeding. Moreover, since the mothers gave
342 the information on breastfeeding several years after the breastfeeding period, recall bias may
343 also have contributed to the low R^2 s.

344 Duration of breastfeeding showed a similar age-dependent influence on child PFOS and
345 PFOA concentrations as maternal PFOS and PFOA serum concentrations at delivery. Serum
346 PFOA concentrations increased 5.1% per month of breastfeeding ($R^2=0.05$) in 4-year-olds,
347 but at 8 and 12 years of age no associations were found. Serum concentrations of PFOS in 4-
348 year-olds increased 7.9% per month of breastfeeding ($R^2=0.10$), 5.3% per month for 8-year-
349 olds ($R^2=0.08$), and for 12-year-olds the association was not significant. For PFHxS the
350 association was not significant when the children were divided into the three age groups,
351 although the 4-year-olds showed an increase of 7.6% in serum levels per month of
352 breastfeeding with $p=0.053$ (Table 5). As with maternal PFAA concentrations, growth
353 dilution, excretion and exposure from sources other than breastfeeding most likely contributed
354 to this decrease in importance of early life exposure.

355 Studies of 3-year-old children from Norway and children <3.5 years old from the U.S. have
356 found similar results as among our 4-year-old children, with PFOS and PFOA concentrations

357 increasing 3-6% per month of breastfeeding.^{20 60} A study from the Faroe Islands showed
358 much stronger associations between breastfeeding duration and child PFAA concentrations,
359 with concentrations of PFOS and PFOA increasing with 30% per month of breastfeeding in
360 fully nursed children at ages 1.5 and 5 years.²¹ In children from the Faroe Islands
361 concentrations of PFNA and PFDA increased about 20% per month of breastfeeding,²¹
362 whereas Norwegian²⁰ and U.S. children⁶⁰ showed similar results to the present study with no
363 associations between time of breastfeeding and increase in serum concentrations for PFNA
364 and PFDA.

365 We tested the hypothesis that body weight could influence serum PFAA concentrations,
366 through an effect on volume of distribution. This was only indicated for PFOA, for which
367 concentrations significantly decreased with increased body weight ($R^2=0.05$), giving some
368 support to this hypothesis. Among 3-month-old POPUP infants sampled 1996-1999 no
369 association between PFOA serum concentrations and weight gain from birth was observed.³⁸
370 Instead, PFHpA concentrations were negatively associated with weight gain. Although, both
371 studies give some support to an influence of growth dilution on child PFAA concentrations,
372 more controlled studies are needed in order to draw firm conclusions about the influence of
373 growth dilution on serum PFAA concentrations during childhood. The fact that PFAA do not
374 appreciably partition into fat may have contributed to the weak or non-significant associations
375 with weight of the children.⁶¹

376 Overall, divergent associations were observed between year of sampling, 2008-2015, and
377 PFAS concentrations over the 7 year sampling period. For example, PFOA displayed an
378 inverse associations with sampling year (-7.6% per year) whereas PFHxS displayed a positive
379 association (7.5% per year) (Table 4). PFOS also displayed an inverse association (-3.4% per
380 year), but this was not statistically significant. Similar trends were previously reported in
381 POPUP mothers between 1996 and 2012,^{42 55} and are attributed to a) decreased exposure to

382 PFOS and PFOA, and their precursors, due to the phase out of production of these PFASs,
383 and b) cumulative long-term drinking water PFHxS exposure in the Uppsala area.³⁷

384 The basic regression models used by us only included covariates significantly associated with
385 PFAA concentrations at the $p \leq 0.1$ significance levels in univariate analyses. An analysis
386 using a regression model with all possible covariates (full model) was done in order to
387 determine if the partial regression coefficients changed significantly compared with the basic
388 models (Supporting Information, Table A9). When comparing the results of the two MRL
389 analyses including children of all ages (Supporting Information, Tables A8 and A9) only
390 slight differences in mean percent changes or significance levels were found. As expected the
391 R^2 of the full models were in many cases slightly higher, but they did not differ markedly
392 from those of the basic model. This shows that the covariates with significance levels $p > 0.1$ in
393 univariate analyses only explained a small fraction of the variation in serum PFAA
394 concentrations. Only two statistically significant association became non-significant when
395 using the full model, i.e. PFBS and age, and PFOA and body weight. A few marginally non-
396 significant associations in the basic model became significant in the full model. Similarly as
397 for 8-year-olds, the adjusted mean PFOA concentration among 12-year-olds was lower than
398 that of 4-year-old. %br PFHxS decreased as number of months of breastfeeding increased.
399 Most importantly, however, among the covariates not included in the basic models for
400 PFHpA and PFDA, sampling year was significantly associated (negative) in the full model.
401 This may indicate that PFHpA and PFDA exposure of Swedish children decreased between
402 2008 and 2015.

403

404 **Drinking water exposure**

405 When including all children in the MLR models, serum concentrations in children increased
406 with increasing drinking water exposure for PFOA, PFBS, PFHxS, and PFOS (Table 4). The

407 strongest associations were observed for PFBS and PFHxS, for which drinking water
408 exposure explained 20% and 41%, respectively, of the variation in serum concentrations.
409 Serum concentrations increased by 207% and 7.4% per month of cumulative PFBS and
410 PFHxS drinking water exposure, respectively. This shows that drinking water is an important
411 exposure medium for PFBS and PFHxS for children even in cases when drinking water
412 contamination is moderate to low as in the Uppsala case. In the contaminated production
413 wells in Uppsala, the median PFHxS concentration was 80 ng L⁻¹, followed by PFOS (50 ng
414 L⁻¹) and PFBS (10 ng L⁻¹) in samples collected 2012-2014.³⁷ PFOA was detected in one fifth
415 of the samples in these production wells, at a detection limit of 10 ng L⁻¹. Concentrations in
416 drinking water before 2012 are not known, but the PFBS and PFHxS concentrations in serum
417 from POPUP mothers living in areas receiving potentially contaminated drinking water were
418 elevated already between 1996 and 1999 and only slightly lower than concentrations in
419 mothers living in the same areas from 2008 to 2011.³⁷ This suggests that contamination of the
420 drinking water may not have been markedly lower between 1996 and 1999 compared to 2012.
421 The (on average) 1.2% increase in PFOA serum concentration per month of cumulative
422 PFOA drinking water exposure among the children (Table 4) suggests that even low PFOA
423 contamination may be enough to significantly influence total PFOA exposure in children with
424 background exposure from other sources. PFOS serum concentrations in the children
425 increased on average 0.9% per month of cumulative PFOS drinking water exposure (Table 4).
426 These results differ from mothers to the children in the present study, where drinking water
427 exposure was not associated with increased PFOS levels, although PFOS concentrations in
428 the production wells were clearly elevated from background.³⁷ The much higher exposure to
429 PFOS from food than of PFBS and PFHxS³ may mask contributions of drinking water
430 exposure to serum PFOS concentrations.

431 The %br PFHxS and %br PFOS in children's serum were positively associated with
432 cumulative drinking water exposure, with a stronger association for %br PFHxS ($R^2=0.15$)
433 than for %br PFOS ($R^2=0.02$) (Table 4). The results support earlier findings that enrichment
434 of br PFHxS isomers in serum samples relative to proportions observed in the general
435 population could possibly be used as marker of exposure to PFAA polluted drinking water
436 caused by contamination from fire-fighting training areas.³⁷ We hypothesize that higher
437 percentages of br PFOS isomers in children with higher cumulative exposure to contaminated
438 drinking water also was caused by enrichment of br PFOS isomers in contaminated drinking
439 water. The proportion of br PFOS isomers in Uppsala drinking water has been determined to
440 be on average 53%,³⁷ which is considerably higher than the 30% contribution in the major
441 commercial product.⁵⁴ It is possible that the enrichment of br isomers in drinking water is due
442 to the preferential leaching of br PFOS into the drinking water supply⁶² and/or preferential
443 biodegradation of br PFOS-precursors during water treatment.⁵ The elevated exposure to
444 drinking water PFOS in this study may also have contributed to the higher %br PFOS (37%)
445 in the Uppsala children compared to percentages reported in other studies of children from
446 Denmark and the U.S (32% and 29% respectively), which most likely are exposed from other,
447 generally dominating pathways (i.e. ingestion of food, dust, etc.).^{46, 48}

448 In conclusion, early life exposure to PFOA, PFHxS, and PFOS is an important determinant of
449 serum concentrations in children, with the strongest influence on younger ages. Drinking
450 water with low to moderate PFBS, PFHxS, PFOS, and PFOA contamination is an important
451 source of exposure for children with background exposure from other sources.

452 **Table 1. Characteristics of the children**

Age	Characteristics	n	Mean	Range	%	
4 years	Age (years)	57	3.9	3.3-5.1		
	Sampling year	6			11	
	2008-2009	24			42	
	2010-2012	27			47	
	2013-2015					
	Weight (kg)	57	17	13-23		
	Time of breastfeeding (months)	57	6.8	1- >13		
	Girls	21			37	
	Boys	36			63	
	DW exposure ^a	PFHpA	57	0.38	0-1.9	
	(cumulative PFAA months)	PFOA	57	4.1	0-17	
		PFBS	57	0.17	0-0.91	
		PFHxS	57	5.1	0-23	
	PFOS	57	4.5	0-19		
8 years	Age (years)	55	8.4	7.3-9.6		
	Sampling year	16			29	
	2008-2009	20			36	
	2010-2012	19			35	
	2014-2015					
	Weight (kg)	54	29	20-44		
	Time of breastfeeding (months)	55	7.1	0.5->13		
	Girls	21			38	
	Boys	34			62	
	DW exposure ^a	PFHpA	55	0.29	0-2.0	
	(cumulative PFAA months)	PFOA	55	3.2	0-32	
		PFBS	55	0.13	0-0.91	
		PFHxS	55	4.6	0-48	
	PFOS	55	3.7	0-38		
12 years	Age (years)	119	12.2	11.1-13.2		
	Sampling year	31			26	
	2008-2009	76			64	
	2010-2012	12			10	
	2014					
	Weight (kg)	113	44	28-67		
	Time of breastfeeding (months)	117	6.3	0- >13		
	Girls	56			47	
	Boys	63			53	
	DW exposure ^a	PFHpA	119	0.44	0-1.9	
	(cumulative PFAA months)	PFOA	119	5.0	0-31	
		PFBS	119	0.20	0-0.91	
		PFHxS	119	8.0	0-54	
	PFOS	119	6.0	0-38		

453 ^aCumulative exposure to PFAA from drinking water during the whole life-time until
454 sampling.

455 **Table 2. Perfluoroalkyl carboxylic acid (PFCA) serum concentrations in children at 4**
 456 **(*n*=57), 8 (*n*=55), and 12 (*n*=119) years of age (ng g⁻¹ serum)**

Children	Age	Mean	SD	Median	Range	DF ^a (%)
PFHpA	4	0.18	0.18	0.12	<0.08-1.0	79
	8	0.12	0.11	0.08	<0.08-0.75	60
	12	0.09	0.06	0.08	<0.08-0.52	51
PFOA	4	2.7	1.3	2.5	0.86-8.3	100
	8	2.1	0.81	2.0	<0.80-4.0	98
	12	2.1	0.70	2.0	0.86-4.0	100
PFNA	4	0.85	0.79	0.67	0.26-5.5	100
	8	0.76	0.33	0.69	0.34-2.1	100
	12	0.67	0.46	0.59	<0.08-3.9	99
PFDA	4	0.26	0.11	0.25	<0.10-0.54	98
	8	0.30	0.11	0.29	<0.10-0.67	96
	12	0.25	0.092	0.23	<0.10-0.52	99
PFUnDA	4	0.21	0.12	0.18	<0.10-0.77	74
	8	0.20	0.079	0.18	<0.10-0.46	78
	12	0.17	0.071	0.16	<0.10-0.51	65
PFDoDA	4			<0.08	<0.08-0.21	12
	8			<0.08	<0.08-0.07	2
	12			<0.08	<0.08-0.06	1
PFTrDA	4	0.03	0.05	<0.02	<0.02-0.35	35
	8	0.03	0.02	0.02	<0.02-0.13	51
	12	0.02	0.02	<0.02	<0.02-0.10	29
PFTeDA	4			<0.06	<0.06-0.43	11
	8			<0.06		0
	12			<0.06	<0.06-0.10	3
PFPeDA	4			<0.01	<0.01-0.06	4
	8			<0.01	<0.01-0.04	2
	12			<0.01	<0.01-0.02	1

457 ^aDetection frequency.

458 **Table 3. Perfluoroalkane sulfonic acid (PFSA) serum concentrations in children at 4**
 459 **(*n*=57), 8 (*n*=55), and 12 (*n*=119) years of age (ng g⁻¹ serum)**

Children	Age	Mean	SD	Median	Range	DF ^a (%)
PFBS	4	0.03	0.03	0.02	<0.01-0.11	65
	8	0.02	0.02	<0.01	<0.01-0.09	44
	12	0.03	0.03	0.02	<0.01-0.23	60
lin PFHxS	4	6.5	6.3	4.6	0.55-35	100
	8	3.6	5.0	1.5	0.41-29	100
	12	3.5	5.0	1.5	0.41-23	100
br PFHxS	4	0.39	0.42	0.20	<0.01-1.6	98
	8	0.23	0.35	0.07	<0.01-1.6	96
	12	0.27	0.43	0.08	<0.01-2.6	90
%br PFHxS	4	5.1	2.1	5.0	0.25-9.5	100
	8	4.8	2.3	4.5	0.53-11	100
	12	5.7	3.1	5.3	0.23-12	100
Total PFHxS	4	6.9	6.7	5.0	0.60-37	100
	8	3.9	5.4	1.6	0.43-30	100
	12	3.8	5.4	1.6	0.43-26	100
lin PFOS	4	2.9	1.6	2.4	0.87-7.1	100
	8	3.8	2.7	3.2	1.3-19	100
	12	3.7	1.8	3.4	1.2-9.7	100
br PFOS	4	1.8	0.93	1.5	0.51-4.2	100
	8	2.1	1.0	1.8	0.76-4.7	100
	12	2.1	0.95	1.9	0.80-5.1	100
%br PFOS	4	38	6.4	38	26-56	100
	8	37	7.2	38	18-50	100
	12	37	6.9	37	17-54	100
Total PFOS	4	4.7	2.4	3.8	1.4-11	100
	8	5.9	3.5	4.9	2.5-23	100
	12	5.9	2.6	5.3	2.1-14	100

460 ^aDetection frequency.

461 **Table 4. Mean percent changes (standard error) [partial R^2]^a of serum concentrations of PFAA in children, ($n=198$, aged 4, 8, and 12 years),**
 462 **per unit change of each variable, assessed via multiple linear regression analysis^b**

	Drinking water exposure (Cumulative PFAA months)	Maternal serum conc (ng g ⁻¹ serum)	Time of breastfeeding (Months)	Sampling year (Years)	Weight (kg)	Sex	R^{2c}	n
PFCA								
PFHpA ^d	1.5 (5.0) p=0.76	e	e	-	-0.47 (0.60) p=0.43	-	0.14	188
PFOA	1.2 (0.41) [0.06] p=0.004	10 (3.4) [0.04] p=0.001	1.4 (1.2) p=0.25	-7.6 (1.5) [0.12] p<0.001	-1.0 (0.46) [0.05] p=0.039	-	0.30	148
PFNA	f	15 (19) p=0.36	-0.31 (1.5) p=0.83	-	-	-	0.02	149
PFDA	f	12 (35) p=0.67	2.2 (1.3) p=0.090	-	-	-8.1 (5.8) p=0.17	0.06	151
PFSA								
PFBS ^d	207 (52) [0.20] p<0.001	e	e	-	-	-	0.22	198
Total PFHxS	7.4 (0.53) [0.41] p<0.001	10 (1.6) [0.11] p<0.001	3.9 (2.0) [0.01] p=0.046	7.5 (3.0) [0.01] p=0.009	-1.1 (0.75) p=0.16	-	0.75	147
%br PFHxS	0.11 (0.02) [0.15] p<0.001	-0.06 (0.08) p=0.48	-0.16 (0.08) p=0.054	-0.32 (0.12) [0.03] p=0.009	-	-	0.20	153
Total PFOS	0.93 (0.44) [0.02] p=0.034	1.3 (0.55) [0.03] p=0.015	3.8 (1.5) [0.04] p=0.010	-3.4 (2.1) p=0.10	-0.32 (0.57) p=0.58	-11 (6.2) p=0.081	0.16	148
%br PFOS	0.14 (0.06) [0.02] p=0.033	0.28 (0.10) [0.04] p=0.004	-0.006 (0.22) p=0.98	-	-	-	0.07	151

463 - = the covariate was not significantly associated in the univariate linear regression ($p \geq 0.1$) and was therefore not included in the total model.

464 ^aPartial coefficient of determination from stepwise regression analyses.

465 ^bThe categories age 4, 8, and 12 years, with age 4 as the reference category, were also adjusted for in the multiple linear regression analyses.

466 ^cCoefficient of determination for the whole regression model.

467 ^d>25% below MQL.

468 ^eNot included in the regression model due to short half-life.

469 ^fNot detected in the drinking water.


470 **Table 5. Percent change (standard error) [partial R^2]^a in PFAA serum concentrations**
 471 **per unit change of maternal PFAA serum concentration (ng g⁻¹ serum) and nursing**
 472 **duration (months) in children at 4 ($n=57$), 8 ($n=55$), and 12 ($n=119$) years of age,**
 473 **assessed via multiple linear regression analysis^b**

	Age	Maternal serum conc (ng g ⁻¹ serum)	Time of breastfeeding (months)	R^{2c}	n
PFOA	4	29 (7.8) [0.24] p<0.001	5.1 (2.4) [0.05] p=0.034	0.42	52
	8	3.1 (7.1) p=0.66	1.7 (2.2) p=0.42	0.42	40
	12	8.4 (3.9) [0.04] p=0.026	-1.9 (1.3) p=0.15	0.21	87
Total PFHxS	4	11 (1.7) [0.29] p<0.001	7.6 (4.1) p=0.053	0.69	52
	8	9.7 (5.6) p=0.071	-0.18 (3.0) p=0.95	0.73	40
	12	7.2 (5.6) p=0.18	2.7 (2.5) p=0.28	0.68	85
Total PFOS	4	5.6 (1.5) [0.24] p=0.001	7.9 (2.8) [0.10] p=0.005	0.39	51
	8	-0.86 (1.2) p=0.49	5.3 (2.6) [0.08] p=0.038	0.27	40
	12	1.1 (0.59) p=0.054	1.7 (1.7) p=0.34	0.13	86
%br PFOS	4	0.20 (0.14) p=0.14	0.33 (0.41) p=0.43	0	51
	8	0.45 (0.20) [0.09] p=0.031	0.20 (0.41) p=0.64	0.09	40
	12	0.33 (0.15) [0.04] p=0.038	-0.15 (0.27) p=0.58	0.15	86

474 ^aPartial coefficient of determination from stepwise regression analyses.

475 ^bDrinking water exposure (Cumulative PFAA months) were also adjusted for in the models and the
 476 covariates sampling year, age, and sex if they were significantly associated in the univariate linear
 477 regression ($p \geq 0.1$).

478 ^cCoefficient of determination for the whole regression model.




479

480 **Figure 1.** Years of birth and sampling period with median, for the children in the present
 481 study at 4 (n=57), 8 (n=55), and 12 (n=119) years of age.

482

483




484

485 **Figure 2.** Concentrations of PFAA in children at 4 ($n=50$), 8 ($n=49$), and 12 ($n=99$) years of
 486 age, sampled 2008-2015. Concentrations are shown as least square means and standard error
 487 (SE) determined by general linear model (GLM) analysis adjusted for sampling year and
 488 drinking water exposure (cumulative PFAA months). a = significantly different from 4-year-
 489 olds and b = significantly different from 8-year-olds ($p<0.05$).

490

491



492

493 **Figure 3.** Cluster analysis of PFAS based on correlations between serum concentration in
494 children at 4, 8, and 12 years of age ($n=198$), sampled 2008-2015, using average linkage
495 cluster analysis, which is a hierarchical analysis clustering method based on the average
496 distance between all pairs of objects.

497

498 **Supporting Information**

499 PFAs included in the study (Table A1). Target compounds and selected instrumental
500 parameters for quantification of each compound by UPLC/ESI-MS/MS (Table A2). Summary
501 of analysis of in-house reference material (pooled human serum) analyzed together with real
502 samples to assess inter-batch precision (i.e. reproducibility) (Table A3). PFCA concentrations
503 measured in 3 replicates of NIST SRM 1957 compared to reference values (Table A4). PFSA
504 concentrations measured in 3 replicates of NIST SRM 1957 compared to reference values
505 (Table A5). Calculation example of cumulative exposure to PFAA from drinking water (Table
506 A6). Blood PFAA concentrations in children from other studies (Table A7). Mean percent
507 changes of serum PFAA concentrations including all children and results from the age
508 categories, with age 4 as the reference category (Table A8). Mean percent changes of serum
509 PFAA concentrations including all children and all variables in all multiple linear regression
510 analyses (Table A9). Mean percent changes of serum PFAA concentrations for the three age
511 groups (4, 8, and 12) separately Table A10).

512

513 **Acknowledgements**

514 This research was financially supported by the Swedish Research Council Formas (SafeDrink,
515 grant no 222-2012-2124), and the Swedish Environmental Protection Agency (contract no
516 2215-15-001). Participating mothers and children are thanked for their dedication to the study.
517 Ingalill Gadhasson, Anne-Sofie Kärsrud, and Tomas Alsberg are thanked for excellent
518 laboratory and instrument support. We are also very grateful to midwife Marianne Leimar and
519 nurse Christine Strömbom responsible for recruitment and blood sampling of mothers and
520 children for doing an excellent job.

521

522 **Disclosures**

523 The authors declare that they have no actual or competing financial interest.

524

525 **References**

- 526 1. D'Hollander, W.; de Voogt, P.; De Coen, W.; Bervoets, L., Perfluorinated substances in
527 human food and other sources of human exposure. *Rev Environ Contam Toxicol* **2010**, *208*, 179-215.
- 528 2. Gebbink, W. A.; Berger, U.; Cousins, I. T., Estimating human exposure to PFOS isomers
529 and PFCA homologues: the relative importance of direct and indirect (precursor) exposure. *Environ*
530 *Int* **2015**, *74*, 160-9.
- 531 3. Vestergren, R.; Berger, U.; Glynn, A.; Cousins, I. T., Dietary exposure to perfluoroalkyl
532 acids for the Swedish population in 1999, 2005 and 2010. *Environ Int* **2012**, *49*, 120-7.
- 533 4. D'Eon J, C.; Mabury, S. A., Is indirect exposure a significant contributor to the burden
534 of perfluorinated acids observed in humans? *Environ Sci Technol* **2011**, *45*, (19), 7974-84.
- 535 5. Martin, J. W.; Asher, B. J.; Beesoon, S.; Benskin, J. P.; Ross, M. S., PFOS or PreFOS? Are
536 perfluorooctane sulfonate precursors (PreFOS) important determinants of human and environmental
537 perfluorooctane sulfonate (PFOS) exposure? *J Environ Monit* **2010**, *12*, (11), 1979-2004.
- 538 6. Giesy, J. P.; Kannan, K., Global distribution of perfluorooctane sulfonate in wildlife.
539 *Environ Sci Technol* **2001**, *35*, (7), 1339-42.
- 540 7. Kannan, K.; Corsolini, S.; Falandysz, J.; Fillmann, G.; Kumar, K. S.; Loganathan, B. G.;
541 Mohd, M. A.; Olivero, J.; Van Wouwe, N.; Yang, J. H.; Aldoust, K. M., Perfluorooctanesulfonate and
542 related fluorochemicals in human blood from several countries. *Environ Sci Technol* **2004**, *38*, (17),
543 4489-95.
- 544 8. Gutzkow, K. B.; Haug, L. S.; Thomsen, C.; Sabaredzovic, A.; Becher, G.; Brunborg, G.,
545 Placental transfer of perfluorinated compounds is selective--a Norwegian Mother and Child sub-
546 cohort study. *Int J Hyg Environ Health* **2012**, *215*, (2), 216-9.
- 547 9. Beesoon, S.; Webster, G. M.; Shoeib, M.; Harner, T.; Benskin, J. P.; Martin, J. W.,
548 Isomer profiles of perfluorochemicals in matched maternal, cord, and house dust samples:
549 manufacturing sources and transplacental transfer. *Environ Health Perspect* **2011**, *119*, (11), 1659-64.
- 550 10. Chen, F.; Yin, S.; Kelly, B. C.; Liu, W., Isomer-Specific Transplacental Transfer of
551 Perfluoroalkyl Acids: Results from a Survey of Paired Maternal, Cord Sera, and Placentas. *Environ Sci*
552 *Technol* **2017**, *51*, (10), 5756-5763.
- 553 11. Yang, L.; Wang, Z.; Shi, Y.; Li, J.; Wang, Y.; Zhao, Y.; Wu, Y.; Cai, Z., Human placental
554 transfer of perfluoroalkyl acid precursors: Levels and profiles in paired maternal and cord serum.
555 *Chemosphere* **2016**, *144*, 1631-8.
- 556 12. Kärrman, A.; Ericson, I.; van Bavel, B.; Darnerud, P. O.; Aune, M.; Glynn, A.; Lignell, S.;
557 Lindstrom, G., Exposure of perfluorinated chemicals through lactation: levels of matched human milk
558 and serum and a temporal trend, 1996-2004, in Sweden. *Environ Health Perspect* **2007**, *115*, (2), 226-
559 30.
- 560 13. Kubwabo, C.; Kosarac, I.; Lalonde, K., Determination of selected perfluorinated
561 compounds and polyfluoroalkyl phosphate surfactants in human milk. *Chemosphere* **2013**, *91*, (6),
562 771-7.
- 563 14. Sundström, M.; Ehresman, D. J.; Bignert, A.; Butenhoff, J. L.; Olsen, G. W.; Chang, S. C.;
564 Bergman, A., A temporal trend study (1972-2008) of perfluorooctanesulfonate,

- 565 perfluorohexanesulfonate, and perfluorooctanoate in pooled human milk samples from Stockholm,
566 Sweden. *Environ Int* **2011**, *37*, (1), 178-83.
- 567 15. Apelberg, B. J.; Goldman, L. R.; Calafat, A. M.; Herbstman, J. B.; Kuklennyik, Z.; Heidler,
568 J.; Needham, L. L.; Halden, R. U.; Witter, F. R., Determinants of fetal exposure to polyfluoroalkyl
569 compounds in Baltimore, Maryland. *Environ Sci Technol* **2007**, *41*, (11), 3891-7.
- 570 16. Fei, C.; McLaughlin, J. K.; Tarone, R. E.; Olsen, J., Perfluorinated chemicals and fetal
571 growth: a study within the Danish National Birth Cohort. *Environ Health Perspect* **2007**, *115*, (11),
572 1677-82.
- 573 17. Fromme, H.; Mosch, C.; Morovitz, M.; Alba-Alejandre, I.; Boehmer, S.; Kiranoglu, M.;
574 Faber, F.; Hannibal, I.; Genzel-Boroviczeny, O.; Koletzko, B.; Volkel, W., Pre- and postnatal exposure
575 to perfluorinated compounds (PFCs). *Environ Sci Technol* **2010**, *44*, (18), 7123-9.
- 576 18. Liu, J.; Li, J.; Liu, Y.; Chan, H. M.; Zhao, Y.; Cai, Z.; Wu, Y., Comparison on gestation and
577 lactation exposure of perfluorinated compounds for newborns. *Environ Int* **2011**, *37*, (7), 1206-12.
- 578 19. Cariou, R.; Veyrand, B.; Yamada, A.; Berrebi, A.; Zalko, D.; Durand, S.; Pollono, C.;
579 Marchand, P.; Leblanc, J. C.; Antignac, J. P.; Le Bizec, B., Perfluoroalkyl acid (PFAA) levels and profiles
580 in breast milk, maternal and cord serum of French women and their newborns. *Environ Int* **2015**, *84*,
581 71-81.
- 582 20. Verner, M. A.; Ngueta, G.; Jensen, E. T.; Fromme, H.; Volkel, W.; Nygaard, U. C.;
583 Granum, B.; Longnecker, M. P., A Simple Pharmacokinetic Model of Prenatal and Postnatal Exposure
584 to Perfluoroalkyl Substances (PFASs). *Environ Sci Technol* **2016**, *50*, (2), 978-86.
- 585 21. Mogensen, U. B.; Grandjean, P.; Nielsen, F.; Weihe, P.; Budtz-Jorgensen, E.,
586 Breastfeeding as an Exposure Pathway for Perfluorinated Alkylates. *Environ Sci Technol* **2015**, *49*,
587 (17), 10466-73.
- 588 22. Papadopoulou, E.; Sabaredzovic, A.; Namork, E.; Nygaard, U. C.; Granum, B.; Haug, L.
589 S., Exposure of Norwegian toddlers to perfluoroalkyl substances (PFAS): The association with
590 breastfeeding and maternal PFAS concentrations. *Environ Int* **2016**, *94*, 687-94.
- 591 23. Haug, L. S.; Huber, S.; Becher, G.; Thomsen, C., Characterisation of human exposure
592 pathways to perfluorinated compounds--comparing exposure estimates with biomarkers of
593 exposure. *Environ Int* **2011**, *37*, (4), 687-93.
- 594 24. Mondal, D.; Lopez-Espinosa, M. J.; Armstrong, B.; Stein, C. R.; Fletcher, T.,
595 Relationships of perfluorooctanoate and perfluorooctane sulfonate serum concentrations between
596 mother-child pairs in a population with perfluorooctanoate exposure from drinking water. *Environ*
597 *Health Perspect* **2012**, *120*, (5), 752-7.
- 598 25. Holzer, J.; Midasch, O.; Rauchfuss, K.; Kraft, M.; Reupert, R.; Angerer, J.; Kleeschulte,
599 P.; Marschall, N.; Wilhelm, M., Biomonitoring of perfluorinated compounds in children and adults
600 exposed to perfluorooctanoate-contaminated drinking water. *Environ Health Perspect* **2008**, *116*, (5),
601 651-7.
- 602 26. Winkens, K.; Vestergren, R.; Berger, U.; Cousins, I. T., Early life exposure to per- and
603 polyfluoroalkyl substances (PFASs): A critical review. *Emerging Contaminants* **2017**, *3*, (2), 55-68.
- 604 27. Bach, C. C.; Bech, B. H.; Nohr, E. A.; Olsen, J.; Matthiesen, N. B.; Bonefeld-Jorgensen, E.
605 C.; Bossi, R.; Henriksen, T. B., Perfluoroalkyl Acids in Maternal Serum and Indices of Fetal Growth: The
606 Aarhus Birth Cohort. *Environ Health Perspect* **2016**, *124*, (6), 848-54.
- 607 28. Johnson, P. I.; Sutton, P.; Atchley, D. S.; Koustas, E.; Lam, J.; Sen, S.; Robinson, K. A.;
608 Axelrad, D. A.; Woodruff, T. J., The Navigation Guide - evidence-based medicine meets environmental
609 health: systematic review of human evidence for PFOA effects on fetal growth. *Environ Health*
610 *Perspect* **2014**, *122*, (10), 1028-39.
- 611 29. Gyllenhammar, I.; Diderholm, B.; Gustafsson, J.; Berger, U.; Ridefelt, P.; Benskin, J. P.;
612 Lignell, S.; Lampa, E.; Glynn, A., Perfluoroalkyl acid levels in first-time mothers in relation to offspring
613 weight gain and growth. *Environ Int* **2018**, *111*, 191-199.
- 614 30. Braun, J. M., Early-life exposure to EDCs: role in childhood obesity and
615 neurodevelopment. *Nat Rev Endocrinol* **2017**, *13*, (3), 161-173.

- 616 31. Halldorsson, T. I.; Rytter, D.; Haug, L. S.; Bech, B. H.; Danielsen, I.; Becher, G.;
617 Henriksen, T. B.; Olsen, S. F., Prenatal exposure to perfluorooctanoate and risk of overweight at 20
618 years of age: a prospective cohort study. *Environ Health Perspect* **2012**, *120*, (5), 668-73.
- 619 32. Braun, J. M.; Chen, A.; Romano, M. E.; Calafat, A. M.; Webster, G. M.; Yolton, K.;
620 Lanphear, B. P., Prenatal perfluoroalkyl substance exposure and child adiposity at 8 years of age: The
621 HOME study. *Obesity (Silver Spring)* **2016**, *24*, (1), 231-7.
- 622 33. Mora, A. M.; Oken, E.; Rifas-Shiman, S. L.; Webster, T. F.; Gillman, M. W.; Calafat, A.
623 M.; Ye, X.; Sagiv, S. K., Prenatal Exposure to Perfluoroalkyl Substances and Adiposity in Early and Mid-
624 Childhood. *Environ Health Perspect* **2017**, *125*, (3), 467-473.
- 625 34. Maisonet, M.; Terrell, M. L.; McGeehin, M. A.; Christensen, K. Y.; Holmes, A.; Calafat,
626 A. M.; Marcus, M., Maternal concentrations of polyfluoroalkyl compounds during pregnancy and
627 fetal and postnatal growth in British girls. *Environ Health Perspect* **2012**, *120*, (10), 1432-7.
- 628 35. NTP, Immunotoxicity Associated with Exposure to Perfluorooctanoic Acid or
629 Perfluorooctane Sulfonate. In Services, U. S. D. o. H. a. H., Ed. National Toxicology Program: 2016.
- 630 36. Grandjean, P.; Heilmann, C.; Weihe, P.; Nielsen, F.; Mogensen, U. B.; Budtz-Jorgensen,
631 E., Serum Vaccine Antibody Concentrations in Adolescents Exposed to Perfluorinated Compounds.
632 *Environ Health Perspect* **2017**, *125*, (7), 077018.
- 633 37. Gyllenhammar, I.; Berger, U.; Sundstrom, M.; McCleaf, P.; Euren, K.; Eriksson, S.;
634 Ahlgren, S.; Lignell, S.; Aune, M.; Kotova, N.; Glynn, A., Influence of contaminated drinking water on
635 perfluoroalkyl acid levels in human serum--A case study from Uppsala, Sweden. *Environ Res* **2015**,
636 *140*, 673-83.
- 637 38. Gyllenhammar, I.; Benskin, J. P.; Sandblom, O.; Berger, U.; Ahrens, L.; Lignell, S.;
638 Wiberg, K.; Glynn, A., Perfluoroalkyl Acids (PFAAs) in Serum from 2-4-Month-Old Infants: Influence of
639 Maternal Serum Concentration, Gestational Age, Breast-Feeding, and Contaminated Drinking Water.
640 *Environ Sci Technol* **2018**, *52*, (12), 7101-7110.
- 641 39. Glynn, A.; Aune, M.; Darnerud, P. O.; Cnattingius, S.; Bjerselius, R.; Becker, W.; Lignell,
642 S., Determinants of serum concentrations of organochlorine compounds in Swedish pregnant
643 women: a cross-sectional study. *Environ Health* **2007**, *6*, 2.
- 644 40. Lignell, S.; Aune, M.; Darnerud, P. O.; Cnattingius, S.; Glynn, A., Persistent
645 organochlorine and organobromine compounds in mother's milk from Sweden 1996-2006:
646 compound-specific temporal trends. *Environ Res* **2009**, *109*, (6), 760-7.
- 647 41. Riddell, N.; Arsenault, G.; Benskin, J. P.; Chittim, B.; Martin, J. W.; McAlees, A.;
648 McCrindle, R., Branched perfluorooctane sulfonate isomer quantification and characterization in
649 blood serum samples by HPLC/ESI-MS(/MS). *Environ Sci Technol* **2009**, *43*, (20), 7902-8.
- 650 42. Glynn, A., Perfluorerade alkylsyror (PFAA) i Uppsala dricksvatten. In *Riskvärdering*,
651 Division, R. B. A., Ed. Swedish National Food Agency: 2012; Vol. dnr 1192/2012.
- 652 43. Russell, M. H.; Himmelstein, M. W.; Buck, R. C., Inhalation and oral toxicokinetics of
653 6:2 FTOH and its metabolites in mammals. *Chemosphere* **2015**, *120*, 328-35.
- 654 44. Olsen, G. W.; Chang, S. C.; Noker, P. E.; Gorman, G. S.; Ehresman, D. J.; Lieder, P. H.;
655 Butenhoff, J. L., A comparison of the pharmacokinetics of perfluorobutanesulfonate (PFBS) in rats,
656 monkeys, and humans. *Toxicology* **2009**, *256*, (1-2), 65-74.
- 657 45. Li, Y.; Fletcher, T.; Mucs, D.; Scott, K.; Lindh, C. H.; Tallving, P.; Jakobsson, K., Half-lives
658 of PFOS, PFHxS and PFOA after end of exposure to contaminated drinking water. *Occup Environ Med*
659 **2018**, *75*, (1), 46-51.
- 660 46. Harris, M. H.; Rifas-Shiman, S. L.; Calafat, A. M.; Ye, X.; Mora, A. M.; Webster, T. F.;
661 Oken, E.; Sagiv, S. K., Predictors of Per- and Polyfluoroalkyl Substance (PFAS) Plasma Concentrations
662 in 6-10 Year Old American Children. *Environ Sci Technol* **2017**, *51*, (9), 5193-5204.
- 663 47. Wu, X. M.; Bennett, D. H.; Calafat, A. M.; Kato, K.; Strynar, M.; Andersen, E.; Moran, R.
664 E.; Tancredi, D. J.; Tulse, N. S.; Hertz-Picciotto, I., Serum concentrations of perfluorinated compounds
665 (PFC) among selected populations of children and adults in California. *Environ Res* **2015**, *136*, 264-73.

- 666 48. Morck, T. A.; Nielsen, F.; Nielsen, J. K.; Siersma, V. D.; Grandjean, P.; Knudsen, L. E.,
667 PFAS concentrations in plasma samples from Danish school children and their mothers. *Chemosphere*
668 **2015**, *129*, 203-9.
- 669 49. Schecter, A.; Malik-Bass, N.; Calafat, A. M.; Kato, K.; Colacino, J. A.; Gent, T. L.; Hynan,
670 L. S.; Harris, T. R.; Malla, S.; Birnbaum, L., Polyfluoroalkyl compounds in Texas children from birth
671 through 12 years of age. *Environ Health Perspect* **2012**, *120*, (4), 590-4.
- 672 50. Wilhelm, M.; Wittsiepe, J.; Volkel, W.; Fromme, H.; Kasper-Sonnenberg, M.,
673 Perfluoroalkyl acids in children and their mothers: Association with drinking water and time trends of
674 inner exposures--Results of the Duisburg birth cohort and Bochum cohort studies. *Int J Hyg Environ*
675 *Health* **2015**, *218*, (7), 645-55.
- 676 51. Trasande, L.; Koshy, T. T.; Gilbert, J.; Burdine, L. K.; Attina, T. M.; Ghassabian, A.;
677 Honda, M.; Marmor, M.; Chu, D. B.; Han, X.; Shao, Y.; Kannan, K., Serum perfluoroalkyl substances in
678 children exposed to the world trade center disaster. *Environ Res* **2017**, *154*, 212-221.
- 679 52. Kim, D. H.; Lee, M. Y.; Oh, J. E., Perfluorinated compounds in serum and urine samples
680 from children aged 5-13 years in South Korea. *Environ Pollut* **2014**, *192*, 171-8.
- 681 53. Zeng, X. W.; Qian, Z.; Emo, B.; Vaughn, M.; Bao, J.; Qin, X. D.; Zhu, Y.; Li, J.; Lee, Y. L.;
682 Dong, G. H., Association of polyfluoroalkyl chemical exposure with serum lipids in children. *Sci Total*
683 *Environ* **2015**, *512-513*, 364-70.
- 684 54. Benskin, J. P.; De Silva, A. O.; Martin, J. W., Isomer profiling of perfluorinated
685 substances as a tool for source tracking: a review of early findings and future applications. *Rev*
686 *Environ Contam Toxicol* **2010**, *208*, 111-60.
- 687 55. Gebbink, W. A.; Glynn, A.; Berger, U., Temporal changes (1997-2012) of perfluoroalkyl
688 acids and selected precursors (including isomers) in Swedish human serum. *Environ Pollut* **2015**,
689 *199C*, 166-173.
- 690 56. Zhang, Y.; Beesoon, S.; Zhu, L.; Martin, J. W., Biomonitoring of perfluoroalkyl acids in
691 human urine and estimates of biological half-life. *Environ Sci Technol* **2013**, *47*, (18), 10619-27.
- 692 57. Gao, Y.; Fu, J.; Cao, H.; Wang, Y.; Zhang, A.; Liang, Y.; Wang, T.; Zhao, C.; Jiang, G.,
693 Differential accumulation and elimination behavior of perfluoroalkyl Acid isomers in occupational
694 workers in a manufactory in China. *Environ Sci Technol* **2015**, *49*, (11), 6953-62.
- 695 58. Kim, S. K.; Lee, K. T.; Kang, C. S.; Tao, L.; Kannan, K.; Kim, K. R.; Kim, C. K.; Lee, J. S.;
696 Park, P. S.; Yoo, Y. W.; Ha, J. Y.; Shin, Y. S.; Lee, J. H., Distribution of perfluorochemicals between sera
697 and milk from the same mothers and implications for prenatal and postnatal exposures. *Environ*
698 *Pollut* **2011**, *159*, (1), 169-174.
- 699 59. Pan, Y.; Zhu, Y.; Zheng, T.; Cui, Q.; Buka, S. L.; Zhang, B.; Guo, Y.; Xia, W.; Yeung, L. W.;
700 Li, Y.; Zhou, A.; Qiu, L.; Liu, H.; Jiang, M.; Wu, C.; Xu, S.; Dai, J., Novel Chlorinated Polyfluorinated
701 Ether Sulfonates and Legacy Per-/Polyfluoroalkyl Substances: Placental Transfer and Relationship
702 with Serum Albumin and Glomerular Filtration Rate. *Environ Sci Technol* **2017**, *51*, (1), 634-644.
- 703 60. Mondal, D.; Weldon, R. H.; Armstrong, B. G.; Gibson, L. J.; Lopez-Espinosa, M. J.; Shin,
704 H. M.; Fletcher, T., Breastfeeding: a potential excretion route for mothers and implications for infant
705 exposure to perfluoroalkyl acids. *Environ Health Perspect* **2014**, *122*, (2), 187-92.
- 706 61. Loccisano, A. E.; Longnecker, M. P.; Campbell, J. L., Jr.; Andersen, M. E.; Clewell, H. J.,
707 3rd, Development of PBPK models for PFOA and PFOS for human pregnancy and lactation life stages.
708 *J Toxicol Environ Health A* **2013**, *76*, (1), 25-57.
- 709 62. Kärrman, A.; Elgh-Dalgren, K.; Lafossas, C.; Mørskeland, T., Environmental levels and
710 distribution of structural isomers of perfluoroalkyl acids after aqueous fire-fighting foam (AFFF)
711 contamination. *Environmental Chemistry* **2011**, *8*, (4), 372-380.

712

713